Permeability-modifying factors in SCLS. (A-B) Comparison of basal and episodic VEGF or Ang2 in individual patients with SCLS. (VEGF: P = .015; Ang2: P = .008, Wilcoxon signed rank test). (C) The barrier-defending roles of IVIG, anti-Ang2 (Tie2-Fc), and anti-VEGF (bevacizumab) or equivalent concentrations of control IgG (for anti-Ang2 and bevacizumab) or BSA (for IVIG) against episodic sera from 4 to 6 patients was evaluated in the TEER assay. Shown is the response to the episodic sera of patient 1 (n = 3-5 replicates per condition). *P < .05 and **P < .01.